Modafinil and Adrafinil: The Definitive Guide

What is modafinil and adrafinil?

Modafinil is a prescription wakefulness-promoting medicine. In the United States it is approved to improve wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift-work disorder. It does not cure these conditions, replace adequate sleep or correct the underlying airway obstruction in OSA. [7]

Adrafinil is an older synthetic prodrug that is converted into modafinil. That relationship does not make the two products interchangeable. An approved modafinil tablet has a defined label, manufacturing controls and prescriber oversight. Adrafinil sold as a nootropic is not FDA-approved and does not inherit modafinil’s indications, dose or safety assurances.

The healthy-cognition evidence is much narrower than the “smart drug” reputation. A 2019 meta-analysis of 19 placebo-controlled single-dose studies in non-sleep-deprived adults found a statistically significant but small overall effect, Hedges g=0.10. It found no significant differences among attention, executive function, memory and processing speed, and no significant moderation by 100 versus 200 mg. [1]

Mechanistic reviews describe effects across dopamine and other catecholamine systems, while emphasizing that no single pathway explains every wakefulness or cognitive finding. Those models help frame research; they do not establish a healthy-user indication or dosing schedule. [3], [4]

Typical Modafinil Prescription Protocols

The label notes that doses up to 400 mg/day have been tolerated in some settings but provides no consistent evidence of added benefit beyond 200 mg/day. That statement is not permission to escalate. Severe hepatic impairment requires a reduced dose, and older adults may need lower dosing because elimination can be reduced. [7]

Prescription identity

Record modafinil versus armodafinil, manufacturer, strength, pharmacy label and lot; do not substitute adrafinil by a conversion ratio.

Indication and timing

Keep the diagnosed sleep disorder, each administration, planned sleep window and actual sleep separate.

Safety context

Record rash, allergic symptoms, mood or behavior change, blood pressure if directed, persistent sleepiness and every interacting medicine.

What are modafinil and adrafinil commonly used for?

Excessive sleepiness in approved conditions

Modafinil’s strongest evidence and clearest use are as a prescription medicine for wakefulness in the labeled sleep-disorder populations. Reviews of its clinical program support wakefulness effects in narcolepsy, OSA-associated residual sleepiness and shift-work disorder. The outcome is improved wakefulness, not restoration of missed sleep or treatment of the cause of OSA. [2], [7]

A person can remain sleepy despite taking modafinil. Current labeling tells clinicians to reassess sleepiness frequently and, where appropriate, advise against driving or other dangerous activity. Feeling more alert is not proof that reaction time and judgment are safe.

Cognition in non-sleep-deprived adults

Kredlow and colleagues pooled 19 placebo-controlled trials that administered a single modafinil dose and evaluated attention, executive function, memory or processing speed. The overall effect was g=0.10 (95% CI 0.05–0.15). No cognitive domain clearly stood out and 200 mg did not significantly outperform 100 mg as a moderator. [1]

This is evidence of limited average potential, not a guarantee for an individual or a justification for repeated off-label use. A small standardized effect can be statistically detectable while remaining modest in practical terms. Single-dose trials also do not answer long-term benefit, tolerance, sleep displacement or repeated-risk questions.

What does adrafinil-specific evidence establish?

Adrafinil-specific human evidence is old, sparse and poorly suited to modern self-directed claims. A review describes early French work, but accessible details do not support a current consumer protocol or a reliable modafinil-equivalence ratio. [2]

One published case described persistent orofacial dyskinesia after long-term adrafinil exposure; symptoms improved with tetrabenazine after withdrawal. A single case cannot estimate incidence, but it defeats claims that an unapproved prodrug is harmless because it is not scheduled like modafinil. [6]

How do forms and labels differ?

Modafinil is a racemic medicine; armodafinil is the R-enantiomer and has its own prescription label. Adrafinil is a distinct prodrug. CRL-40,940, CRL-40,941, flmodafinil and fladrafinil are additional analogues, not alternate spellings or automatically equivalent products.

Bakota and Nandrea developed an FDA laboratory LC-HRMS method and applied it to four undercover-purchased products marketed as nootropics or cognitive enhancers and labeled with adrafinil. Adrafinil was found in all four. This verifies active pharmaceutical ingredient exposure in those samples; it does not prove dose uniformity, manufacturing quality, therapeutic benefit or safety. [5]

How should these products be stored?

Store prescription modafinil as directed on the pharmacy label, in its original container and secure from children and others. Do not share a controlled prescription. Keep unidentified adrafinil or analogue powders away from medicines and food; discarding an unverified product is safer than attempting to relabel it. Storage cannot correct identity or strength.

What does the human evidence show?

What are the risks and interactions?

Current labeling warns of serious rash, including Stevens–Johnson syndrome, toxic epidermal necrolysis and DRESS; angioedema or anaphylaxis; multiorgan hypersensitivity; psychiatric symptoms; cardiovascular concerns; and persistent sleepiness. A rash cannot reliably be classified as harmless at home. Stop modafinil at the first sign of rash unless a clinician clearly determines it is not drug-related, and seek urgent care for blistering, peeling skin, mouth sores, facial or airway swelling, fever with systemic illness or breathing difficulty. [7]

Psychiatric symptoms can include anxiety, insomnia, agitation, confusion, depression, mania, delusions, hallucinations, aggression or suicidal thinking. Review psychosis, depression, mania and substance-use history before treatment. Cardiovascular disease and blood pressure may require added monitoring.

Modafinil can induce CYP3A4/5 and inhibit CYP2C19. The label warns that steroidal contraceptive effectiveness may be reduced during treatment and for one month after stopping; alternative or concomitant contraception is recommended. Cyclosporine exposure may fall, CYP2C19 substrates such as omeprazole, phenytoin and diazepam may rise, warfarin warrants more frequent INR consideration, and MAO inhibitors require caution. [7]

Adrafinil adds uncertainty in conversion, product quality and liver exposure. Do not combine either compound with other stimulants, high-caffeine pre-workouts, decongestants or psychoactive drugs without a prescriber or pharmacist reviewing the full regimen.

What is the legal and anti-doping status?

In the United States, modafinil is a Schedule IV prescription medicine. Adrafinil is not FDA-approved and is not an ordinary dietary ingredient. FDA’s Peak Nootropics warning letter named adrafinil in a drug-claim enforcement context, and OPSS lists both modafinil and adrafinil among ingredients prohibited in dietary supplements for U.S. service members. [9], [10]

WADA’s 2026 list places adrafinil and modafinil in S6.A, non-specified stimulants prohibited in competition. The 2026 list also explicitly added fladrafinil and flmodafinil. Athletes need current governing-body advice and should not treat product certification as permission to use a prohibited ingredient. [8]

In Canada, verify the specific modafinil product in the Drug Product Database and follow prescription rules. An online adrafinil listing is not proof of a DIN or NPN. [11]

When should use stop?

Follow the label’s urgent stop instructions for rash or suspected hypersensitivity. Contact the prescriber promptly for psychiatric change, chest pain, palpitations, sustained blood-pressure change or persistent sleepiness. Do not drive or perform hazardous work merely because the medicine makes you feel awake. Do not stop a prescribed treatment or substitute adrafinil without the prescriber.

What should be monitored?

Record the diagnosed indication, prescription product, dose time, planned sleep, actual sleep, residual sleepiness and whether driving or safety-sensitive work is planned. Track rash or allergic symptoms, mood or behavior, cardiovascular symptoms and clinician-directed blood pressure. Keep the medication list current, including contraception, warfarin, cyclosporine and CYP2C19 substrates.

For OSA, record adherence to the airway treatment separately from the wakefulness medicine. Improved alertness cannot show that the obstruction is controlled.

What does community experience add?

Public reports may surface insomnia, headache, anxiety, long duration, altered appetite and sourcing problems. They cannot verify an adrafinil product, quantify a safe conversion or distinguish restored wakefulness from displaced sleep. No systematic current community sample was assembled, so this guide reports no consensus cycle, conversion ratio or healthy-user schedule.

How do these compounds compare with related options?

Common questions

Is modafinil a supplement?

No. It is a prescription medicine and Schedule IV controlled substance in the United States.

Is adrafinil simply over-the-counter modafinil?

No. It is a distinct unapproved prodrug with different product controls and no FDA-approved schedule. Conversion does not establish interchangeability.

Does modafinil make healthy people smarter?

The best quantitative synthesis found a small average single-dose effect, g=0.10, without a clear cognitive-domain advantage. That is limited evidence, not a broad transformation claim. [1]

Is 400 mg better than 200 mg?

The prescription label says there is no consistent evidence of additional benefit beyond 200 mg/day despite tolerability of higher amounts in some settings. Do not escalate without the prescriber. [7]

Can modafinil reduce contraceptive effectiveness?

Yes. Current labeling recommends alternative or concomitant contraception during treatment with steroidal contraceptives and for one month after stopping. [7]

Should any rash be taken seriously?

Yes. The label advises stopping at the first sign unless the rash is clearly not drug-related because benign and serious rashes cannot be reliably distinguished early. [7]

Does modafinil treat sleep apnea?

It treats associated excessive sleepiness in selected patients; it does not treat the underlying airway obstruction. Effective OSA therapy must continue. [7]

Are modafinil and adrafinil allowed in sport?

Both are named S6.A stimulants prohibited in competition under the 2026 WADA list. [8]

Glossary

Plain explanations of modafinil and adrafinil terms.

Wakefulness-promoting medicine

A drug used to improve wakefulness; it does not replace physiologic sleep.

Prodrug

A compound converted in the body into an active drug; conversion does not make products dose-equivalent.

Hedges g

A standardized effect size; 0.10 represents a small average difference.

OSA

Obstructive sleep apnea, repeated upper-airway obstruction during sleep.

CYP3A4/5 induction

Increased enzyme activity that can lower exposure to some medicines, including steroidal contraceptives.

CYP2C19 inhibition

Reduced enzyme activity that can raise exposure to certain medicines.

DRESS

A potentially severe drug reaction with rash, systemic symptoms and organ involvement.

WADA S6.A

The non-specified stimulant subsection prohibited in competition.

How this guide was researched

Six PubMed identities were checked through live NCBI EFetch for title, authors, journal, volume, issue, pages, DOI and descendant publication-status records. The current DailyMed label supplied indications, exact schedules, warnings and interactions. The 19-trial meta-analysis supplied the healthy-cognition effect. The FDA-laboratory product study, FDA enforcement record, OPSS and WADA supplied identity and regulatory context.

Explore the sources

Related guides

• Phenylpiracetam
• Noopept
• Caffeine
• L-theanine
• Nootropic compounds

Editorial note

This guide keeps prescription wakefulness, small single-dose cognitive effects and unapproved adrafinil products in separate evidence lanes. It does not convert modafinil labeling into an adrafinil or healthy-user regimen.